These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24704084)

  • 1. De novo autoimmune hepatitis after interferon treatment in a liver transplant recipient with common variable immunodeficiency.
    Aguilera I; Sousa JM; Gómez-Bravo MA; Núñez-Roldán A
    Dig Liver Dis; 2014 Jul; 46(7):663-4. PubMed ID: 24704084
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus.
    Cholongitas E; Samonakis D; Patch D; Senzolo M; Burroughs AK; Quaglia A; Dhillon A
    Transplantation; 2006 Feb; 81(3):488-90. PubMed ID: 16477242
    [No Abstract]   [Full Text] [Related]  

  • 3. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
    Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
    Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case 10-2011: Fever, confusion, and liver failure.
    Kandel C; Kandel G
    N Engl J Med; 2011 Jul; 365(2):185-6; author reply 187. PubMed ID: 21751933
    [No Abstract]   [Full Text] [Related]  

  • 6. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
    Striki A; Manolakopoulos S; Deutsch M; Mela M; Kalafateli M; Schini M; Anagnostou O; Triantos C; Andreadis I; Ketikoglou I; Papatheodoridis G; Pectasides D
    J Viral Hepat; 2014; 21(9):624-32. PubMed ID: 24224747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C.
    Pfaundler N; Kessebohm K; Blum R; Stieger M; Stickel F
    Liver Int; 2013 Apr; 33(4):648-9. PubMed ID: 23410147
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients.
    Selzner N; Guindi M; Renner EL; Berenguer M
    J Hepatol; 2011 Jul; 55(1):207-17. PubMed ID: 21145865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C.
    Lörke J; Erhardt A; Häussinger D
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):xx. PubMed ID: 15625645
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
    Larrey D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B283-90. PubMed ID: 12180302
    [No Abstract]   [Full Text] [Related]  

  • 11. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
    Maasoumy B; Port K; Deterding K; Höner Zu Siederdissen C; Markova AA; Rogalska-Taranta M; Manns MP; Wedemeyer H; Cornberg M
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):836-45. PubMed ID: 24987822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of chronic hepatitis C in special groups].
    Bourlière M; Halfon P; Portal I
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B238-47. PubMed ID: 12180296
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C virus infection after liver transplantation.
    Agarwal K; Barnabas A
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S349-54. PubMed ID: 24091115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.
    Papastathopoulos K; Bouzas E; Naoum G; Vergados I; Tsiodras S
    J Infect; 2006 Feb; 52(2):e59-61. PubMed ID: 15951019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 1999 May; 124(20):636-42. PubMed ID: 10370387
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C.
    Demirturk N; Cevik F; Demirdal T; Aykin N; Aslan V
    Platelets; 2006 Aug; 17(5):340-3. PubMed ID: 16928608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
    Shinohara MM; Davis C; Olerud J
    J Drugs Dermatol; 2009 Sep; 8(9):870-2. PubMed ID: 19746680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic hepatitis C].
    Bell H; Dalgard O; Bjøro K; Hellum KB; Myrvang B
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):926-8. PubMed ID: 12082838
    [No Abstract]   [Full Text] [Related]  

  • 20. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Kim B; Trivedi A; Thung SN; Grewal P
    Semin Liver Dis; 2014 Feb; 34(1):108-12. PubMed ID: 24782264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.